Search

Displaying results 1371 - 1380 of 10000 in total
  1. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … [L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations.

  2. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not … [L46133] Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 ATLAST study in people with presymptomatic SOD1-ALS.

  3. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.

  4. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type … [L46616] In May 2023, sotagliflozin was approved by the FDA to reduce the risk of cardiovascular death and heart failure in patients with high risk factors.[]

    Categories: Drugs Used in Diabetes
  5. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer. … [L50181, L50186, L50201] Irinotecan liposome was approved by the FDA in February 2024.[L50186] The active metabolite SN-38 is also a potent inhibitor of DNA topoisomerase I.

  6. Drug

    Chlorpromazine

    go.drugbank.com/drugs/DB00477
    ApprovedInvestigationalVet approved

    Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. … Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors.

    Synonyms: 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine, 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
  7. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).

  8. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. … Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately [L4718].

    Synonyms: N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide, N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.

  10. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative